CA3221272A1 - Method for producing dihydropyridazine-3,5-dione derivative - Google Patents

Method for producing dihydropyridazine-3,5-dione derivative Download PDF

Info

Publication number
CA3221272A1
CA3221272A1 CA3221272A CA3221272A CA3221272A1 CA 3221272 A1 CA3221272 A1 CA 3221272A1 CA 3221272 A CA3221272 A CA 3221272A CA 3221272 A CA3221272 A CA 3221272A CA 3221272 A1 CA3221272 A1 CA 3221272A1
Authority
CA
Canada
Prior art keywords
formula
compound
toluenesulfonate
solvent
crystal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3221272A
Other languages
English (en)
French (fr)
Inventor
Masatoshi Murakata
Shio KOMIYA
Zengye HOU
Taro Enomoto
Satoshi Tanida
Hiroshi Fukuda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of CA3221272A1 publication Critical patent/CA3221272A1/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • B01J31/2404Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
    • B01J31/2409Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring with more than one complexing phosphine-P atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/28Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2231/00Catalytic reactions performed with catalysts classified in B01J31/00
    • B01J2231/40Substitution reactions at carbon centres, e.g. C-C or C-X, i.e. carbon-hetero atom, cross-coupling, C-H activation or ring-opening reactions
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/001General concepts, e.g. reviews, relating to catalyst systems and methods of making them, the concept being defined by a common material or method/theory
    • B01J2531/002Materials
    • B01J2531/004Ligands
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82Metals of the platinum group
    • B01J2531/824Palladium
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80Complexes comprising metals of Group VIII as the central metal
    • B01J2531/84Metals of the iron group
    • B01J2531/842Iron
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Epidemiology (AREA)
CA3221272A 2021-06-08 2022-06-08 Method for producing dihydropyridazine-3,5-dione derivative Pending CA3221272A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021-096200 2021-06-08
JP2021096200 2021-06-08
PCT/JP2022/023068 WO2022260062A1 (ja) 2021-06-08 2022-06-08 ジヒドロピリダジン-3,5-ジオン誘導体の製造方法

Publications (1)

Publication Number Publication Date
CA3221272A1 true CA3221272A1 (en) 2022-12-15

Family

ID=84426032

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3221272A Pending CA3221272A1 (en) 2021-06-08 2022-06-08 Method for producing dihydropyridazine-3,5-dione derivative

Country Status (13)

Country Link
US (1) US20250115585A1 (https=)
EP (1) EP4353718A4 (https=)
JP (1) JP7665747B2 (https=)
KR (1) KR20240019168A (https=)
CN (1) CN117460727A (https=)
AR (1) AR126060A1 (https=)
AU (1) AU2022291310A1 (https=)
BR (1) BR112023023841A2 (https=)
CA (1) CA3221272A1 (https=)
IL (1) IL309054A (https=)
MX (1) MX2023013898A (https=)
TW (1) TW202313590A (https=)
WO (1) WO2022260062A1 (https=)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2525659B1 (en) * 2010-01-19 2019-02-27 Merck Sharp & Dohme Corp. PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS
CN102869656B (zh) 2010-04-28 2014-03-12 安斯泰来制药株式会社 四氢苯并噻吩化合物
EP2591354B1 (en) 2010-07-07 2016-09-07 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
KR101941048B1 (ko) 2011-10-27 2019-01-22 아스텔라스세이야쿠 가부시키가이샤 아미노 알킬 치환 n-티에닐벤즈아미드 유도체
WO2014003153A1 (ja) 2012-06-28 2014-01-03 協和発酵キリン株式会社 置換アミド化合物
PT2975030T (pt) * 2013-03-13 2020-09-28 Chugai Pharmaceutical Co Ltd Derivado de di-hidropiridazina-3,5-diona
DE102013111551B3 (de) 2013-10-21 2015-01-22 Wago Verwaltungsgesellschaft Mbh Tragschienengehäuse
MX383069B (es) 2014-09-12 2025-03-13 Chugai Pharmaceutical Co Ltd Farmaceutico que contiene inhibidor de transportador de fosfato dependiente de sodio.
US10934280B2 (en) 2016-08-15 2021-03-02 Eli Lilly And Company Condensed thiophene derivatives useful as NaPi-IIb inhibitors
CN111801335A (zh) 2018-01-17 2020-10-20 株式会社神钢环境舒立净 亚硼酸酯化合物的合成方法、亚硼酸酯化合物的钠盐及其合成方法

Also Published As

Publication number Publication date
EP4353718A1 (en) 2024-04-17
BR112023023841A2 (pt) 2024-01-30
JP7665747B2 (ja) 2025-04-21
EP4353718A4 (en) 2025-11-05
US20250115585A1 (en) 2025-04-10
IL309054A (en) 2024-02-01
CN117460727A (zh) 2024-01-26
MX2023013898A (es) 2023-12-11
WO2022260062A1 (ja) 2022-12-15
AU2022291310A1 (en) 2024-01-18
JPWO2022260062A1 (https=) 2022-12-15
KR20240019168A (ko) 2024-02-14
TW202313590A (zh) 2023-04-01
AR126060A1 (es) 2023-09-06

Similar Documents

Publication Publication Date Title
JP6761448B2 (ja) アザインドールを作製するための方法および中間体
KR20200136493A (ko) 7-시클로펜틸-2-(5-피페라진-1-일-피리딘-2-일아미노)-7h-피롤로[2,3-d]피리미딘-6-카르복실산 디메틸아미드의 염(들) 및 그의 제조 방법
JP6894917B2 (ja) ピリジニルアミノピリミジン誘導体のメシル酸塩の結晶形、その製造方法及びその使用
US9284320B2 (en) Ticagrelor adducts with divalent metal salts
JP2008539278A (ja) 結晶性ロスバスタチンカルシウム
EP4353718A1 (en) Method for producing dihydropyridazine-3,5-dione derivative
CN109996800B (zh) 吡啶并[3,4-d]嘧啶衍生物或其溶剂合物的晶体
EA051007B1 (ru) Способ получения производного дигидропиридазин-3,5-диона
EA052755B1 (ru) Способ получения производного дигидропиридазин-3,5-диона
HK40103591A (zh) 二氢哒嗪-3,5-二酮衍生物的制造方法
CN109422739B (zh) 氘代的吲哚胺2,3-双加氧酶抑制剂及其应用
CN105228988A (zh) 曲格列汀半琥珀酸盐的晶体及其制备方法和药物组合物
RU2793759C2 (ru) Кристаллическая форма пиридо[3,4-d]пиримидинового производного
EP4230625A1 (en) Crystal form of multi-substituted benzene ring compound maleate, and preparation method therefor and use thereof
JP6289619B2 (ja) ピリジン誘導体の新規な結晶多形体およびその製造方法
HU231012B1 (hu) Lapatinib sók
HK40011691B (en) Crystal of pyrido[3, 4-d]pyrimidine derivative or solvate thereof
HK1235400B (en) Processes and intermediates for producing azaindoles
WO2013089636A1 (en) Processes for manufacturing of a kinase inhibitor
HK1194371A (en) Processes and intermediates for producing azaindoles
HK1234048A1 (en) Novel crystalline polymorph of pyridine derivative, and method for producing same

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250430

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250430